DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
IPO Year: 2005
Exchange: NASDAQ
Website: dexcom.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/26/2024 | $161.00 → $80.00 | Outperform → Neutral | Robert W. Baird |
| 7/26/2024 | $145.00 → $75.00 | Overweight → Neutral | JP Morgan |
| 5/30/2024 | $130.00 | Neutral | Redburn Atlantic |
| 3/12/2024 | $165.00 | Outperform | RBC Capital Mkts |
| 5/30/2023 | $131.00 | Equal-Weight | Morgan Stanley |
| 4/17/2023 | $127.00 → $138.00 | Outperform → Strong Buy | Raymond James |
| 3/29/2023 | $142.00 | Buy | UBS |
| 1/26/2023 | $121.00 | Outperform | Wolfe Research |
| 10/18/2022 | $103.00 | Equal Weight | Barclays |
| 10/12/2022 | $125.00 | Buy | Jefferies |
Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing efforts will help ŌURA and Dexcom reach millions of new users seeking better metabolic health Dexcom is investing $75 million in ŌURA Series D funding DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world's leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura R
Dexcom unveils new global data1 which reveals nearly 70% of people with diabetes say they didn't know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest Alongside Dexcom Warriors and Stelo Ambassadors, Dexcom invites people with diabetes to share their aspirations – whether small or large – helping them take the first step in their health journey to discover what they're made of In the U.S., Dexcom is hosting a giveaway for Dexcom G7 and Stelo users to increase community engagement and awareness of the incredible things people with diabetes can achieve This World Diabetes Day,
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $152.0 million or 15.3% of revenue, a decrease of 580 basis points compared to the third quarter of 2023. Non-GAAP operating income* of $212.0 million or 21.3% of reported revenue, a decrease of 320 basis points compared to the third quarter of 2023. Thi
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. Management will hold a conference call to review the company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes prior to the
National Glucose Awareness Week will take place from Sept. 23-29, 2024, and will encourage people to learn about the importance of glucose and its significant impact on overall health, especially for people with diabetes. Retta, actress from Parks and Recreation, Good Girls and Hit Man, who is managing Type 2 diabetes, will inspire others to get involved. Visit GetGlucoseAware.com to learn more about the initiative and help spread the word. DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit Beyond Type 2, are teaming up with author, producer and actress Retta to establish National Glucos
Kicking off its third season, Dexcom U welcomes four new athletes, including Shelomi Sanders, a rising star on the Alabama A&M University basketball team, to its diverse roster of 20 athletes with diabetes representing 12 sports across 18 colleges First-of-its-kind program continues to serve as a beacon of education and inspiration for the diabetes community through mentorship opportunities such as the Dexcom U Sports Camp which took place in June 2024 DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's groundbreaking NIL (name, image, likeness)
Dexcom CGM is being worn by astronauts in space as part of the Polaris Dawn mission, which aims to better understand the effects of spaceflight on human health DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better understand the effects of spaceflight on human health. While in orbit, the Polaris Dawn crew will conduct scientific research designed to advance both human health on Earth and our understanding of human health during long-dur
Dexcom EASD Symposium brings together expert panellists from across Europe to explore the transformational effects of Dexcom CGM on clinical practice. With the most extensive clinical data and evidence, Dexcom is the most experienced partner in Automatic Insulin Delivery (AID)1. Studies show the potential for Dexcom CGM to support therapy de-escalation and optimise diabetes management in Type 2 diabetes.5,6,8 DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at an upcoming symposium during the European Association for the Study of Diabetes (
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4th. The live presentation is scheduled to begin at approximately 11:00 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring
Available for purchase today at Stelo.com for people in the U.S. 18 and older not using insulin Provides 24/7 powerful and personalized glucose insights directly to a smartphone,* revealing how food, exercise and sleep can affect glucose Tracking glucose just got easier, with no prescription and no fingersticks, ever Specifically designed to help people with Type 2 diabetes not using insulin and those with prediabetes reach their A1c goals and potentially slow the progression of diabetes.†,1-3 DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $152.0 million or 15.3% of revenue, a decrease of 580 basis points compared to the third quarter of 2023. Non-GAAP operating income* of $212.0 million or 21.3% of reported revenue, a decrease of 320 basis points compared to the third quarter of 2023. Thi
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. Management will hold a conference call to review the company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes prior to the
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic1 basis. U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $158.0 million or 15.7% of revenue, an increase of 100 basis points compared to the second quarter of 2023. Non-GAAP operating income* of $195.4 million or 19.5% of reported revenue, an increase of 130 basis points compared to the second quarter of 2023.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes prior to the
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $101.1 million or 11.0% of revenue, an increase of 460 basis points compared to the first quarter of 2023. Non-GAAP operating income* of $140.2 million or 15.2% of reported revenue, an increase of 460 basis points compared to the firs
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis. International revenue growth was 23% on an organic1 basis. GAAP operating income of $216.9 million or 21.0% of revenue, an increase of 560 basis points compared to the fourth quarter of 2022. Non-GAAP operating income* of $242.7 million or 23.5% of reported revenue, an increase of 240 basis points co
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" appro
The company also announced Stelo, its new glucose sensor for people with type 2 diabetes who do not use insulin, has been submitted to the U.S. Food and Drug Administration for review and is expected to launch in the U.S. in summer 2024 DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring ("CGM"), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265
DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $975.0 million on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 24% and international revenue growth of 33% on a reported basis. International revenue growth was 30% on an organic1 basis. GAAP operating income of $205.5 million or 21.1% of revenue, an increase of 190 basis points compared to the third quarter of 2022. Non-GAAP operating income* of $238.9 million or 24.5% of reported revenue, an increase of 360 basis points compared with the
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
4 - DEXCOM INC (0001093557) (Issuer)
Robert W. Baird downgraded Dexcom from Outperform to Neutral and set a new price target of $80.00 from $161.00 previously
JP Morgan downgraded Dexcom from Overweight to Neutral and set a new price target of $75.00 from $145.00 previously
Redburn Atlantic initiated coverage of Dexcom with a rating of Neutral and set a new price target of $130.00
RBC Capital Mkts initiated coverage of Dexcom with a rating of Outperform and set a new price target of $165.00
Morgan Stanley resumed coverage of Dexcom with a rating of Equal-Weight and set a new price target of $131.00
Raymond James upgraded Dexcom from Outperform to Strong Buy and set a new price target of $138.00 from $127.00 previously
UBS initiated coverage of Dexcom with a rating of Buy and set a new price target of $142.00
Wolfe Research initiated coverage of Dexcom with a rating of Outperform and set a new price target of $121.00
Barclays initiated coverage of Dexcom with a rating of Equal Weight and set a new price target of $103.00
Jefferies initiated coverage of Dexcom with a rating of Buy and set a new price target of $125.00
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
SC 13G/A - DEXCOM INC (0001093557) (Subject)
10-Q - DEXCOM INC (0001093557) (Filer)
8-K - DEXCOM INC (0001093557) (Filer)
144 - DEXCOM INC (0001093557) (Subject)
10-Q - DEXCOM INC (0001093557) (Filer)
8-K - DEXCOM INC (0001093557) (Filer)
SD - DEXCOM INC (0001093557) (Filer)
8-K - DEXCOM INC (0001093557) (Filer)
10-Q - DEXCOM INC (0001093557) (Filer)
8-K - DEXCOM INC (0001093557) (Filer)
ARS - DEXCOM INC (0001093557) (Filer)
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and maintains $145 price target.
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics. Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits. Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage. Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month. Abbott’s consumer bi
Morgan Stanley analyst Patrick Wood maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $132 to $120.
In the last three months, 4 analysts have published ratings on DexCom (NASDAQ:DXCM), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $141.75, a high estimate of $160.00, and a low estimate of $130.00. This current average has decreased by 3.35% from th
Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $145 to $132.
DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 11.92% on an annualized basis producing an average annual return of 25.21%. Currently, DexCom has a market capitalization of $45.21 billion. Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $3,122.92 today based on a price of $113.69 for DXCM at the time of writing. DexCom's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando. Dexcom: The CGM brand for people with Type 2 diabetes, prediabetes and those using GLP-1s This year at ADA, Dexcom is presenting more data on Dexcom CGM use among people with Type 2 diabetes than ever before. This data shows clinically meaningful decreas
DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 25.32%. Currently, DexCom has a market capitalization of $46.34 billion. Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $2,994.48 today based on a price of $116.53 for DXCM at the time of writing. DexCom's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
Billionaire entrepreneur Mark Cuban thinks that efforts by the U.S. government and investors in proprietary large-language models to regulate artificial intelligence (AI) will end up giving the lead in this critical field to Chinese companies. Also Read: LinkedIn VP Aneesh Raman Stresses Importance Of Soft Skills In AI Era: ‘…Engaging With AI Is Not A Digital Skill Set. It’s A Communication Skill Set’ A series of data breaches at a $20 billion internet company co-owned by Japan’s SoftBank Corp (OTC:SFTBY) and South Korea’s Naver (OTC:NHNCF) is causing diplomatic tensions between the two nations. Read: FromSoftware’s Miyazaki Admits ‘Room For Improvement’ If Players Rely On Guides In
DexCom's (NYSE:DXCM) short percent of float has fallen 29.84% since its last report. The company recently reported that it has 7.78 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.98 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
Dexcom unveils new global data1 which reveals nearly 70% of people with diabetes say they didn't know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest Alongside Dexcom Warriors and Stelo Ambassadors, Dexcom invites people with diabetes to share their aspirations – whether small or large – helping them take the first step in their health journey to discover what they're made of In the U.S., Dexcom is hosting a giveaway for Dexcom G7 and Stelo users to increase community engagement and awareness of the incredible things people with diabetes can achieve This World Diabetes Day,
Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Andy Rasdal to its Board of Directors. Mr. Rasdal brings more than 30 years of experience of developing and commercializing novel medical devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211125159/en/Andy Rasdal, Board Member, Synchron (Photo: Business Wire) As former CEO of DexCom, Inc. (NASDAQ:DXCM, Market Cap: $46 billion))) he led the company through FDA approval, a successful IPO, and commercialization of its continuous gluco
In its second season, the 2023 Dexcom U roster consists of 20 athletes with diabetes across 10 sports, 20 colleges, and includes 11 new team members Expanded program gives these collegiate athletes a platform to share their stories, serve as role models and inspire other people with diabetes DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of Dexcom U, the first-ever NIL (name, image, likeness) program exclusively for college athletes with diabetes, which had its inaugural season last year. This press release features multimedia. View the full release here: https://www.b
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll is an accomplished leader with significant experience developing, guiding and executing organic and inorganic growth strategies for global organizations. She currently serves as Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices for Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, Ms. Driscoll oversees the company's global business strategy, the execution of commercial launch p
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with responsibility for global sales, marketing and customer experience. Ms. Lawver comes to Dexcom with extensive healthcare and global business leadership experience. She spent the last two decades at Johnson & Johnson (J&J) in a variety of leadership roles across the medical device, consumer med tech, and pharmaceutical sectors. Most recently, Ms. Lawver was the worldwide vice president, immunology at